The European Commission has extended the marketing authorisation for Actemra/RoActemra (tocilizumab) to include the treatment of severe COVID-19 in adults.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,